Company No:
Contents
Note | 2024 | 2023 | ||
£ | £ | |||
Fixed assets | ||||
Tangible assets | 3 |
|
|
|
Investment property | 4 |
|
|
|
701,345 | 701,495 | |||
Current assets | ||||
Debtors | 5 |
|
|
|
Cash at bank and in hand |
|
|
||
4,133 | 3,904 | |||
Creditors: amounts falling due within one year | 6 | (
|
(
|
|
Net current liabilities | (642,393) | (354,245) | ||
Total assets less current liabilities | 58,952 | 347,250 | ||
Creditors: amounts falling due after more than one year | 7 |
|
(
|
|
Net assets |
|
|
||
Capital and reserves | ||||
Called-up share capital | 8 |
|
|
|
Other reserves | 10 |
|
|
|
Profit and loss account | (
|
(
|
||
Total shareholders' funds |
|
|
Directors' responsibilities:
These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Wentworth Clinic Limited (registered number:
K R Ilankovan
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.
Wentworth Clinic Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Little Somborne Forest Lane, Hightown Hill, Ringwood, BH24 3HF, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.
Plant and machinery etc. |
|
Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.
The fair value is determined annually by the directors on an open market value for existing use basis.
2024 | 2023 | ||
Number | Number | ||
Monthly average number of persons employed by the Company during the year, including directors |
|
|
Plant and machinery etc. | Total | ||
£ | £ | ||
Cost | |||
At 01 May 2023 |
|
|
|
At 30 April 2024 |
|
|
|
Accumulated depreciation | |||
At 01 May 2023 |
|
|
|
Charge for the financial year |
|
|
|
At 30 April 2024 |
|
|
|
Net book value | |||
At 30 April 2024 |
|
|
|
At 30 April 2023 |
|
|
Investment property | |
£ | |
Valuation | |
As at 01 May 2023 |
|
As at 30 April 2024 |
|
Valuation
The investment property was valued at £700,000 (2023: £700,000) by the directors at the date of the financial statements.
Historic cost
If the investment properties had been accounted for under the cost accounting rules, the properties would have been measured as follows:
2024 | 2023 | ||
£ | £ | ||
Historic cost | 460,629 | 472,145 |
2024 | 2023 | ||
£ | £ | ||
Prepayments |
|
|
2024 | 2023 | ||
£ | £ | ||
Amounts owed to directors |
|
|
|
Accruals |
|
|
|
Other creditors |
|
|
|
|
|
2024 | 2023 | ||
£ | £ | ||
Bank loans |
|
|
2024 | 2023 | ||
£ | £ | ||
Allotted, called-up and fully-paid | |||
|
|
|
Transactions with owners holding a participating interest in the entity
2024 | 2023 | ||
£ | £ | ||
Owed to shareholders | 325,364 | 0 |
The loan to the company bears no interest and there are no set repayment terms.
Transactions with the entity's directors
2024 | 2023 | ||
£ | £ | ||
Owed to the directors | 318,342 | 354,311 |
The loan to the company bears no interest and there are no set repayment terms.
Non distributable reserves
The other reserves balance at the year end which is non distributable is made up of £124,213 (2023; £124,213) in relation to fair value movements on investment properties and associated provision for deferred tax.